PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Avenue Therapeutics, Inc. (ATXI)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US05360L2051

CUSIP

05360L205

Sector

Healthcare

IPO Date

Jun 27, 2017

Highlights

Market Cap

$3.57M

EPS (TTM)

$24.78

PE Ratio

0.07

EBITDA (TTM)

-$6.76M

Year Range

$1.60 - $26.47

Target Price

$8.00

Short %

3.56%

Short Ratio

0.73

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
ATXI vs. CRON
Popular comparisons:
ATXI vs. CRON

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Avenue Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%100.00%150.00%JulyAugustSeptemberOctoberNovemberDecember
-99.98%
142.71%
ATXI (Avenue Therapeutics, Inc.)
Benchmark (^GSPC)

Returns By Period

Avenue Therapeutics, Inc. had a return of -84.76% year-to-date (YTD) and -82.96% in the last 12 months.


ATXI

YTD

-84.76%

1M

-3.16%

6M

-49.31%

1Y

-82.96%

5Y*

-81.66%

10Y*

N/A

^GSPC (Benchmark)

YTD

23.11%

1M

-0.36%

6M

7.02%

1Y

23.15%

5Y*

12.80%

10Y*

11.01%

Monthly Returns

The table below presents the monthly returns of ATXI, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-8.07%2.50%-2.77%-54.71%-31.34%1.74%-20.00%-9.29%-1.97%-3.61%-10.60%-84.76%
202318.97%-19.57%4.95%-18.46%14.22%7.83%-10.26%-26.10%-8.89%-66.76%-9.79%-24.06%-86.12%
2022-19.47%-53.51%41.66%-23.22%-24.26%-3.82%-4.79%-6.08%179.07%-76.29%-43.93%-13.43%-91.48%
2021-0.50%-20.61%29.15%-15.65%-3.12%-49.40%-28.69%1.12%-17.68%6.04%-10.76%-35.60%-84.74%
20201.98%-9.30%0.68%6.26%20.74%-6.10%-5.94%9.87%-2.70%-71.01%7.96%75.52%-38.02%
201912.78%-8.87%-14.41%3.79%5.48%21.15%-5.56%5.88%-5.40%-3.86%2.97%62.71%77.78%
20184.14%35.54%-11.74%-15.96%6.86%-11.60%10.34%-9.11%-21.45%25.18%47.59%3.65%49.17%
2017-3.64%-15.97%-12.35%-5.55%-3.80%-21.80%-12.98%-56.12%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ATXI is 13, meaning it’s performing worse than 87% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of ATXI is 1313
Overall Rank
The Sharpe Ratio Rank of ATXI is 1717
Sharpe Ratio Rank
The Sortino Ratio Rank of ATXI is 1010
Sortino Ratio Rank
The Omega Ratio Rank of ATXI is 99
Omega Ratio Rank
The Calmar Ratio Rank of ATXI is 44
Calmar Ratio Rank
The Martin Ratio Rank of ATXI is 2222
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Avenue Therapeutics, Inc. (ATXI) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for ATXI, currently valued at -0.60, compared to the broader market-4.00-2.000.002.00-0.601.90
The chart of Sortino ratio for ATXI, currently valued at -1.08, compared to the broader market-4.00-2.000.002.004.00-1.082.54
The chart of Omega ratio for ATXI, currently valued at 0.84, compared to the broader market0.501.001.502.000.841.35
The chart of Calmar ratio for ATXI, currently valued at -0.84, compared to the broader market0.002.004.006.00-0.842.81
The chart of Martin ratio for ATXI, currently valued at -1.07, compared to the broader market0.0010.0020.00-1.0712.39
ATXI
^GSPC

The current Avenue Therapeutics, Inc. Sharpe ratio is -0.60. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Avenue Therapeutics, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00JulyAugustSeptemberOctoberNovemberDecember
-0.60
1.90
ATXI (Avenue Therapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Avenue Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-99.99%
-3.58%
ATXI (Avenue Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Avenue Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Avenue Therapeutics, Inc. was 99.99%, occurring on Dec 17, 2024. The portfolio has not yet recovered.

The current Avenue Therapeutics, Inc. drawdown is 99.99%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.99%Sep 15, 20201072Dec 17, 2024
-74.55%Jun 28, 2017325Oct 10, 2018304Dec 26, 2019629
-43.11%Feb 11, 202026Mar 18, 202050May 29, 202076
-18.31%Jun 1, 202030Jul 13, 202026Aug 18, 202056
-11.46%Jan 2, 202010Jan 15, 20208Jan 28, 202018

Volatility

Volatility Chart

The current Avenue Therapeutics, Inc. volatility is 19.05%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%30.00%35.00%JulyAugustSeptemberOctoberNovemberDecember
19.05%
3.64%
ATXI (Avenue Therapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Avenue Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Valuation

The Valuation section provides an assessment of the market value of Avenue Therapeutics, Inc. compared to its peers in the Biotechnology industry.


PE Ratio
200.0400.0600.00.1
The chart displays the price to earnings (P/E) ratio for ATXI in comparison to other companies of the Biotechnology industry. Currently, ATXI has a PE value of 0.1. This PE value is considered to be low compared to the rest of the industry.
PEG Ratio
-1,000.0-800.0-600.0-400.0-200.00.00.0
The chart displays the price to earnings to growth (PEG) ratio for ATXI in comparison to other companies of the Biotechnology industry. Currently, ATXI has a PEG value of 0.0. This PEG ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Avenue Therapeutics, Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2024 PortfoliosLab